Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/3/2019
SIETES contiene 92692 citas

 
 
 1 a 19 de 19 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Taylor P. GSK, J&J say monthly injection keeps HIV controlled. PMLiVE 2019:8 de marzo. [Ref.ID 103051]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
3.Tiene citas relacionadas Cita con resumen
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16. [Ref.ID 95085]
4.Tiene citas relacionadas
Powles TJ. Extended adjuvant tamoxifen for breast cancer—a new era?. Lancet 2013;381:782-3. [Ref.ID 95080]
5. Cita con resumen
Krum H, Abraham WT. Heart failure. Lancet 2009;373:941-55. [Ref.ID 85474]
6.Tiene citas relacionadas Cita con resumen
Shimmings A. Rivaroxaban shows promise in ACS secondary prevention in ATLAS. Scrip 2008;3415/116:22-3. [Ref.ID 84556]
7.
Riggs B L, Hartmann LC. Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29. [Ref.ID 65048]
8.
Collecchia G. Il paziente con scompenso cardiaco nel setting della medicina generale. Ricerca e Pratica 2002;18:15-23. [Ref.ID 61434]
9.Tiene citas relacionadas
Fagerberg B. ß-blockade for patients with heart failure. In reply. JAMA 2000;284:436-7. [Ref.ID 52203]
10.Tiene citas relacionadas
Wiener DH. ß-blockade for patients with heart failure. JAMA 2000;284:436. [Ref.ID 52202]
11.Tiene citas relacionadas
Rifkin W, Walerstein S. ß-blockade for patients with heart failure. JAMA 2000;284:436. [Ref.ID 52201]
12. Cita con resumen
Simpson K, Jarvis B. Lisinopril: a review of its use in congestive heart failure. Drugs 2000;59:1149-67. [Ref.ID 50828]
13.Tiene citas relacionadas
Sáenz de la Calzada C. Insuficiencia cardiaca. Un problema de salud pública. An Med Interna 1999;16:551-2. [Ref.ID 48024]
14.
Anónimo. Drugs for chronic heart failure. Med Lett Drugs Ther 1999;41:12-4. [Ref.ID 43662]
15.
Massie BM. 15 years of heart-failure trials: what have we learned?. Lancet 1998;352:29-33. [Ref.ID 41740]
16.
Anónimo. Novartis defends heart failure trial. Scrip 1998;2353:22. [Ref.ID 39199]
17. Cita con resumen
Husten L. Applying the human-genome project to cardiovascular research. Lancet 1998;351:1035. [Ref.ID 38062]
18. Cita con resumen
Anónimo. High dose ACE-inhibitors needed for heart failure. Scrip 1998;2322:21. [Ref.ID 37640]
19.
Goldberg L, Elliot D, Clarke GN, MacKinnon DP, Moe E, Zoref L, Green C, Wolf SL, Miller DJ, Lapin A. Effects of a multidimensional anabolic steroid prevention intervention. The Adolescents Training and Learning to Avoid Steroids (ATLAS) program. JAMA 1996;276:1555-62. [Ref.ID 30489]
Seleccionar todas
 
 1 a 19 de 19